Key result
A deeper implant of the ACURATE-neo valve in valve-in-valve transcatheter implantation facilitates coronary access without appearing to impact hemodynamic performance.
Answers are grounded in this paper and cite their sources.
A deeper implant of the ACURATE-neo valve in valve-in-valve TAVR may facilitate coronary access without impacting hemodynamic performance, warranting future prospective studies.
Key Points Although the durability of heart valves in younger patients remains unknown, those with coronary artery disease will likely progress and require intervention. The ACURATE‐neo valve has the lowest frame profile among the various devices currently in use or under clinical investigation. A deeper implant in valve‐in‐valve transcatheter implantation did not appear to impact its hemodynamic performance but rather facilitates coronary access. Future prospective studies should evaluate the concept of transcatheter valve frame‐to‐coronary distance in various transcatheter heart valves devices.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2021) conducted an editorial in Valve-in-valve transcatheter aortic valve replacement. Deeper implant of ACURATE-neo valve was evaluated. A deeper implant of the ACURATE-neo valve in valve-in-valve transcatheter implantation facilitates coronary access without appearing to impact hemodynamic performance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: